Related Experiment Video
Updated: Dec 6, 2025
09:49
Author Spotlight: Insights into the Use of Apple-Derived Cellulose Scaffolds for Bone Tissue Engineering
Published on: February 23, 2024
2.4K
Bioresorbable Coronary Scaffold Technologies: What's New?
Giulia Masiero1, Giulio Rodinò1, Juji Matsuda2
1Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Via Giustiniani 2, Padua 35128, Italy.
Cardiology Clinics
|October 10, 2020
Summary
Bioresorbable scaffolds offer drug delivery and support but have shown higher adverse events than metallic stents. Improved design and deployment may enhance their benefits by mitigating risks and leveraging complete resorption.
Area of Science:
- Cardiovascular research
- Biomaterials science
- Medical device engineering
Background:
- Metallic drug-eluting stents have a notable rate of adverse events.
- Bioresorbable scaffolds (BRS) were developed as an alternative to provide mechanical support and drug delivery, with the promise of complete resorption.
- Concerns exist regarding the long-term safety and efficacy of BRS, particularly the Absorb BVS technology, which has shown higher event rates compared to drug-eluting stents.
Purpose of the Study:
- To review the current state of bioresorbable scaffolds, evaluating their mechanical properties and biodegradation profiles.
- To discuss the advantages and disadvantages (lights and shadows) of existing BRS technologies.
- To suggest future perspectives for improving BRS technology.
Main Methods:
- Literature review of studies on bioresorbable scaffolds and metallic drug-eluting stents.
- Analysis of mechanical properties and biodegradation characteristics of various BRS.
- Examination of clinical evidence, focusing on event rates and long-term outcomes.
Main Results:
- Bioresorbable scaffolds offer potential benefits like eliminating long-term metallic foreign bodies.
- Current BRS technologies, including the prominent Absorb BVS, have demonstrated higher adverse event rates in the long term compared to traditional drug-eluting stents.
- The mechanical properties and biodegradation rates of BRS significantly influence their performance and clinical outcomes.
Conclusions:
- While bioresorbable scaffolds aim to overcome limitations of metallic stents, current technologies face challenges related to adverse events.
- Improvements in scaffold design and deployment techniques are crucial for mitigating early risks associated with BRS.
- Optimizing BRS may unlock the full potential of complete resorption for enhanced long-term patient benefit.
